Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group-Reference-Cited by-同舟云学术

Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group

Published:1999-08 Issue:8 Volume:35 Page:1194-1201
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Sjöström J.,Blomqvist C.,Mouridsen H.,Pluzanska A.,Ottosson-Lönn S.,Bengtsson N.-O.,Østenstad B.,Mjaaland I.,Palm-Sjövall M.,Wist E.,Valvere V.,Anderson H.,Bergh J.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference17 articles.

1. Review of recent trials of chemotherapy for advanced breast cancer;Clemons;Eur. J. Cancer,1997

2. Review of recent trials of chemotherapy for advanced breast cancer;Clemons;Eur. J. Cancer,1997

3. Docetaxel (Taxotere) an effective agent in the management of second-line breast cancer;Van Oosterom;Semin. Oncol.,1995

4. Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin, and cyclophosphamide for advanced breast cancer;Porkka;J. Clin. Oncol.,1994

5. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors;Fisher;N. Engl. J. Med.,1989

Cited by 244 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances in cold atmospheric plasma (CAP) for breast cancer therapy;Cell Biology International;2022-11-07

2. Rutin: A Flavonoid as an Effective Sensitizer for Anticancer Therapy; Insights into Multifaceted Mechanisms and Applicability for Combination Therapy;Evidence-Based Complementary and Alternative Medicine;2021-08-23

3. The intravenous to oral switch of taxanes: strategies and current clinical developments;Future Oncology;2021-04

4. CTCAE versión 5.0. Evaluación de la gravedad de los eventos adversos dermatológicos de las terapias antineoplásicas;Actas Dermo-Sifiliográficas;2021-01

5. Using the Common Terminology Criteria for Adverse Events (CTCAE – Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies;Actas Dermo-Sifiliográficas (English Edition);2021-01